Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cell Therapeutics, PolaRx Biopharmaceuticals Inc. deal

CTIC acquired PolaRx for 2 million shares of CTIC stock

Read the full 106 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE